• By ICR Secretariat
  • Posted Thursday, October 13, 2022

'The Top Line': Will Eisai's Alzheimer's med lecanemab sway the CMS, how Pfizer is upping its DTC ad push for its COVID shots

https://www.fiercepharma.com/pharma/top-line-new-trial-results-show-eisai-and-biogens-alzheimers-drug-did-surprisingly-well-how

Eisai and Biogen's Alzheimer’s disease drug lecanemab did surprisingly well in a phase 3 trial. The results support the idea that an anti-amyloid drug like lecanemab could be a way to treat Alzheimer’s—a hypothesis that has been under fire since Biogen's debacle with its approved anti-amyloid med, Aduhelm. And, while lecanemab's approvability isn't being debated—unlike the case with Aduhelm after its phase 3 program read out—commercial reimbursement could still be a challenge for the Eisai drug.